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SUMMARY
A rational and appropriate evaluation of liver
biochemical tests is essential, given the increased
number of abnormal laboratory results in asymptomatic
patients. Critical judgement allows early diagnosis in the
absence of typical clinical signs. Autoimmune hepatitis is
a rare disease with high clinical variability. We present a
child investigated for unexplained increase in
aminotransferases, discovered accidentally 2 months
earlier in a standard laboratory panel approach. She was
asymptomatic and no physical signs of chronic or acute
liver disease were found. Laboratory investigation
showed hypergammaglobulinaemia with selective
elevation of IgG and a positive anti-liver cytosol type 1.
Severe interface hepatitis was found on liver biopsy and
treatment was initiated with steroids and azathioprine
with good response. This case highlights the importance
of trusting in any serum aminotransferase abnormality,
even in asymptomatic children and emphasises the value
of clinical suspicion and specific immunosuppressive
therapy in prognosis.
BACKGROUND
Liver biochemical tests often are part of standard
blood chemistries for screening symptomatic and
asymptomatic adult outpatients, for example, in
routine check-ups, before surgical procedures or in
screening tests for blood donors.1 2 This has
resulted in increased incidental findings of abnor-
mal liver chemistry tests that must be interpreted by
physicians. The prevalence and aetiology of hyper-
transaminasemia in childhood are not well defined,
but it is known to be present in several other situa-
tions than viral-induced liver disease. Critical judge-
ment of these findings allows early diagnosis in the
absence of typical clinical signs.2
Autoimmune hepatitis (AIH) is a possible cause
of elevated aminotransferases, characterised by a
progressive hepatic necroinflammatory disorder of
unknown cause with increased levels of serum IgG,
circulating autoantibodies and histological features of
interphase hepatitis. In paediatric population, it is
uncommon, but its real prevalence is still unknown.3
4 Clinical spectrum is very wide and occasionally
AIH is diagnosed in asymptomatic individuals (‘pre-
symptomatic’ stage).4 There is also a large heterogen-
eity in genetic, laboratory, histological and
serological features of the disease.5 We present a type
2 AIH case, in which investigation was triggered by
unexpected results in routine laboratory test.
CASE PRESENTATION
An 11-year-old Caucasian girl was referred due to a
casual finding of persistent elevated serum aspartate
aminotransferase (AST) and alanine aminotransferase
(ALT), detected 2 months earlier in a routine labora-
tory assessment delivered by her primary care phys-
ician although she was completely asymptomatic.
Her medical history was innocent, except for an
isolated episode of epistaxis 2 years earlier, with
medical follow-up. At that time, laboratory results
already revealed abnormal biochemistry with mod-
erate elevated aminotransferases but no investigation
was conducted. She had no history of drug allergies
or blood transfusion and was not taking any medica-
tions (including herbal supplements or vitamins) or
drinking alcohol. On physical examination, no signs
of chronic or acute liver disease were found. A body
mass index ≥85th centile and <95th centile and
normal blood pressure was confirmed.
INVESTIGATIONS
Laboratory investigation confirmed persistent
increased transaminases (AST 127 UI/L and ALT
198 UI/L), with normal albumin (4.7 g/dL), total bili-
rubin (0.5 mg/dL), γ glutamyltransferase (21 UI/L)
and alkaline phosphatase (215 U/L). It also showed a
normal blood count (haemoglobin 12 g/dL, white
cell count 5.9×109/L and platelet count 259×109/L),
activated partial thromboplastin time 33.8 s (normal
range (NR) 26–37 s) and prothrombin time 12.8 s
(NR 10–13 s). Hypergammaglobulinaemia was noted
and serum IgG was elevated (3114 mg/dL; NR 552–
1631 mg/dL). Serological testing for viral hepatitis
was negative (hepatitis B surface antigen (HBsAg),
hepatitis B e antigen (HBeAg), anti-hepatitis C virus
and hepatitis A virus, Epstein-Barr virus, cytomegalo-
virus). Values of fasting glucose and lipid panel were
normal. Ceruloplasmin, copper and α-1-antitrypsin
levels were normal. Tests for antinuclear (ANA), anti-
mitochondrial, anti-smooth muscle (ASMA) and
anti-liver/kidney microsomal type 1 (anti-LKM1) anti-
bodies were negative. Anti-liver cytosol type 1
(anti-LC1) was positive. Coeliac antibodies were nega-
tive. Abdominal ultrasound showed a normal homo-
geneous echo texture of liver and normal spleen size.
Liver biopsy performed 1 month later revealed an
inflammatory lymphocytic infiltrate in portal areas
and severe interface hepatitis; bile ducts were normal
(figures 1 and 2). No cholangiographic study was
performed.
TREATMENT
Treatment was initiated with prednisolone (1 mg/
kg/day) for 1 month. Then, azathioprine (1.5 mg/
kg/day) was added and prednisolone was gradually
decreased to a maintenance dose of 5 mg/day. After
10 months of combined treatment, steroids were
stopped and the patient was treated with azathiopr-
ine alone.
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OUTCOME AND FOLLOW-UP
Aminotransferases and serum IgG returned to normal after 4
and 8 weeks of treatment, respectively. Seventeen months later,
relapse occurred due to non-adherence and steroids were rein-
troduced. After 2 years of treatment, the patient is on azathiopr-
ine and steroids (5 mg/day) with normal transaminases and IgG
levels.
DISCUSSION
The widespread use of routine biochemical assays has probably
increased incidental findings of abnormal liver chemistry tests.
Persistent elevated levels of AST and ALT should be investigated
to provide early diagnosis in the absence of typical clinical signs.
In fact, even mild aminotransferase elevations may indicate the
presence of chronic diseases, including genetic and metabolic
diseases (eg, α-1-antitrypsin deficiency, Wilson disease and
haemochromatosis).
Clinical presentation variability makes AIH diagnosis
extremely difficult and a high index of suspicion is necessary.
Acute hepatitis and insidious onset with progressive jaundice,
headache, anorexia and weight loss are the most frequent pre-
sentations. However, asymptomatic appearance or severe com-
plications like portal hypertension may also be found in
children. AIH seems to be a relatively silent disease, with poor
clinical manifestations contrasting histological severity.3 5 6
Classification of AIH is based on serum autoantibody profiles.
Type 1 is characterised by the presence of ASMA and/or ANA;
type 2 presents antibodies to anti-LKM1 and/or anti-LC1.
Severity and prognosis appear to be similar in the two forms,6 7
but anti-LKM1 positive patients present more frequently with
early fulminant hepatic failure, than those with AIH type 1.3 7
Early diagnosis and treatment are essential to reduce liver
inflammation and improve prognosis. Initial treatment varies
between centres. Steroids and azathioprine have been proposed
as first-line treatment of patients but recent reviews have under-
lined that this combination seems to be far from ideal.5
Immunosuppressive therapy duration is undefined but is recom-
mended in AIH type 1 to ensure histological resolution and at
least 3 years of biochemical remission before beginning a close
and gradual withdrawal.
In AIH type 2, usually a long-term therapy is needed and
rarely stopped.4 7
Learning points
▸ A serious approach towards persistent elevated levels of
aspartate aminotransferase and alanine aminotransferase is
essential to provide early diagnosis in the absence of typical
clinical signs.
▸ All children who are diagnosed with autoimmune hepatitis
(AIH) should be treated. Delays in diagnosis and treatment
adversely affect the long-term outcome.
▸ Relapse during treatment is common. Optimal duration of
immunosuppressive treatment for AIH is unknown but
long-term treatment is required.
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Figure 2 Inflammatory lymphoplasmacytic infiltrate in portal areas
and severe interface hepatitis.
Figure 1 Inflammatory lymphoplasmacytic infiltrate in portal areas
and severe interface hepatitis. No lesions or ductal proliferation were
observed in bile ducts.
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